Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-04-19
2011-04-19
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S007400
Reexamination Certificate
active
07928078
ABSTRACT:
The present invention relates to novel compounds represented by the structure I and pharmaceutical preparations thereof for the treatment of inflammatory diseases in humans and animals.
REFERENCES:
patent: 4710495 (1987-12-01), Bodor
patent: 6566509 (2003-05-01), Griffin et al.
patent: 0283055 (1990-08-01), None
patent: 0771564 (1997-05-01), None
patent: 0775489 (1997-05-01), None
patent: 2776927 (1999-10-01), None
patent: 01163124 (1989-06-01), None
patent: 9213872 (1992-08-01), None
patent: 9213873 (1992-08-01), None
patent: 9413690 (1994-06-01), None
patent: 9414834 (1994-07-01), None
patent: 9741255 (1997-11-01), None
patent: 9964040 (1999-12-01), None
patent: 0042055 (2000-07-01), None
patent: 03070174 (2003-08-01), None
Schentag et al.; “Relationships Between Serum, Intracellular, and Infection Site Concentrations of Macrolide and Azalide Antibiotics. A Theoretical Exploration of the Concept of White Blood Cell Drug Delivery to Infection Sites”; Antiinfect. Drugs Chemother.; 1996; vol. 14, No. 2; pp. 137-146.
Scorneaux et al.; “Intracellular Accumulation, Subcellular Distribution, and Efflux of Tilmicosin in Bovine Mammary, Blood, and Lung Cells.”; Journal of Dairy Science; 1999; vol. 82, No. 6; pp. 1202-1212.
Geerdes-Fenge H F et al.; “Comparative Pharmacokinetics of Dirithromycin and Erythromycin in Normal Volunteers with Special Regard to Accumulation in Polymorphonuclear Leukocytes and in Saliva”; European Journal of Clinical Pharmacology; 1997; vol. 53, No. 2; pp. 127-133.
Vazifeh D et al.; “Cellular Accumulation of the New Ketolide RU 64004 by Human Neutrophils: Comparison With That of Azithromycin and Roxithromycin”; Antimicrobial Agents and Chemotherapy; 1997; vol. 41, No. 10; pp. 2099-2107.
Fietta A et al.; “Requirements for Intracellular Accumulation and Release of Clarithromycin and Azithromycin by Human Phagocytes”; Journal of Chemotherapy; 1997; vol. 9, No. 1; pp. 23-31.
Travers; “Novel Immunomodulators for Topical Skin Disease Therapy”; Expert Opinion on Investigational Drugs; 2000; vol. 9, No. 3; pp. 529-542.
Ianaro et al.; “Anti-Inflammatory Activity of Macrolide Antibiotics”; Journal of Pharmacology and Experimental Therapeutics; 2000; vol. 292, No. 1; pp. 156-163.
Khosla et al.; “Streptogramins: a New Class of Antibiotics”; Indian Journal of Medical Sciences; 1999; vol. 53, No. 3; pp. 111-119.
U.S. Appl. No. 10/830,858, filed Apr. 22, 2004.
Griffith et al.; “Yeast Three-Hybrid System for Detecting Ligand-Receptor Interactions”; Methods in Enzymology; 2000; 328 (Applications of Chimeric Genes and Hybrid Proteins, PT. C); pp. 89-103.
Gladue et al.; “In Vitro and in Vivo Uptake of Azithromycin (CP-62,993) by Phagocytic Cells: Possible Mechanism of Delivery and Release at Sites of Infection”; Antimicrobial Agents and Chemotherapy; 1989; vol. 33, No. 3; pp. 277-282.
Little et al.; “Soft Drugs Based on Hydrocortisone: the Inactive Metabolite Approach and Its Application to Steroidal Antiinflammatory Agents”; Pharmaceutical Research; 1999; vol. 16, No. 6; pp. 961-967.
Anderson et al.; “An In-Vitro Evaluation of the Cellular Uptake and Intraphagocytic Bioactivity of Clarithromycin A-56268 TE-031 A New Macrolide Antimicrobial Agent”; Journal of Antimicrobial Chemotherapy; 1988; vol. 22, No. 6; pp. 923-934.
Olsen et al.; “Intrapulmonary Pharmacokinetics of Azithromycin in Healthy Volunteers Given Five Oral Doses”; Antimicrobial Agents and Chemotherapy; 1996; vol. 40, No. 11; pp. 2582-2585.
Takizawa et al.; “Erythromycin Modulates IL-8 Expression in Normal and Inflamed Human Bronchial Epithelial Cells”; American Journal of Respiratory and Critical Care Medicine; 1997; vol. 156, No. 1; pp. 266-271.
Agouridas et al.; “Synthesis and Antibacterial Activity of Ketolides (6-O-Methyl-3-Oxoerythromycin Derivatives): A New Class of Antibacterials Highly Potent Against Macrolide-Resistant and—Susceptible Respiratory Pathogens”; Journal of Medicinal Chemistry; 1998; vol. 41, No. 21; pp. 4080-4100.
Suzuki et al.; “General and Facile Method for Determination of Configuration of Steroid-17-yl Methyl Glycolates at C-20 Based on Kinetic Examination”; Journal of the Chemical Society, Perkin Transactions I; 1998; pp. 3831-3836.
McLean et al.; “Novel Fluorinated Antiinflammatory Steroid with Reduced Side Effects: Methyl 9alpha-Fluoroprednisolone-16-Carboxylate”; Journal of Pharmaceutical Sciences; 1994; vol. 83, No. 4; pp. 476-480.
Kertesz et al.; “Thiol Esters from Steroid 17beta-Carboxylic Acids: Carboxylate Activation and Internal Participation by 17alpha-Acylates”; Journal of Organic Chemistry; 1986; vol. 51; pp. 2315-2328.
Romo et al.; “Total Synthesis and Immunosuppressive Activity of (−)-Pateamine A and Related Compounds: Implementation of beta-Lactam Based Macrocyclization”; Journal of the American Chemical Society; 1998; vol. 120, No. 47; pp. 12237-12254.
U.S. Appl. No. 11/718,505, filed May 2, 2007.
U.S. Appl. No. 11/201,685, filed Aug. 10, 2005.
U.S. Appl. No. 11/355,808, filed Feb. 15, 2006.
U.S. Appl. No. 11/813,882, filed Jul. 13, 2007.
U.S. Appl. No. 11/813,884, filed Jul. 13, 2007.
Labro; “Anti-Inflammatory Activity of Macrolides: A New Therapeutic Potential?”; Journal of Antimicrobial Chemotherapy; 1998; vol. 41, Suppl. B; pp. 37-46.
Abdelghaffar et al.; “Erythromycin A-Derived Macrolides Modify the Functional Activities of Human Neutrophils by Altering the Phospholipase D-Phosphatidate Phosphohydrolase Transduction Pathway: L-Cladinose Is Involved Both in Alterations of Neutrophil Functions and Modulation of This Transductional Pathway”; Journal of Immunology; 1997; vol. 159, No. 8; pp. 3995-4005.
Mikasa et al.; “The Anti-Inflammatory Effect of Erythromycin in Zymosan-Induced Peritonitis of Mice”; Journal of Antimicrobial Chemotherapy; 1992; vol. 30; pp. 339-348.
Hrvacic Boska
Komac Marijana
Markovic Stribor
Mercep Mladen
Mesic Milan
GlaxoSmithKline Istrazivacki Centar Zagreb D.O.O.
Peselev Elli
Strickland J. Michael
LandOfFree
Conjugates of immune cell specific macrolide compounds with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conjugates of immune cell specific macrolide compounds with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conjugates of immune cell specific macrolide compounds with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2720878